Fennec Pharmaceuticals Presents Pedmark Data in Head and Neck Cancer Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy FENC?
Fennec Pharmaceuticals announced new real world data supporting potential use of Pedmark in adults with head and neck cancers were presented as a digital poster at the 2026 Multidisciplinary Head and Neck Cancers Symposium, MHNCS, in Palm Desert, CA from February 19 - 21, 2026. Findings from a multi-institutional retrospective review of 15 adults with head and neck cancers showed that Pedmark could be safely given greater than or equal to six hours after cisplatin dosing and was easy to incorporate into the real-world care plan for adults with HNC. This strict post-cisplatin timing is a validated approach intended to preserve cisplatin antitumor activity and no disruption to curative-intent cisplatin-based treatment delivery was observed as part of the study review. The study's primary endpoint evaluated feasibility, defined by timing adherence and operational metrics, including administration setting and chair time for infusion-center dosing. Secondary endpoints included infusion-related events, need for antiemetic escalation, and completion of on-treatment and post-treatment audiology assessments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FENC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FENC
Wall Street analysts forecast FENC stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.200
Low
13.00
Averages
14.67
High
18.00
Current: 8.200
Low
13.00
Averages
14.67
High
18.00
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Solas Capital Initiates New Position in Kyndryl
- New Position Disclosure: On February 17, 2026, Solas Capital Management disclosed a new position in Kyndryl by acquiring 407,634 shares valued at $10.83 million, reflecting both confidence in the company and concerns over market volatility.
- Asset Allocation Change: This acquisition represents 6.14% of Solas Capital's reportable assets under management, indicating Kyndryl's significance in the investment portfolio, despite its stock price plummeting by 67.5% over the past year.
- Financial Performance Overview: Kyndryl's latest financial metrics reveal a trailing twelve-month revenue of $15.12 billion and a net income of $249 million, with a market capitalization of $3.06 billion, highlighting ongoing challenges in the IT infrastructure services sector, particularly in its partnership with IBM.
- Uncertain Market Outlook: While Solas Capital's investment in Kyndryl has garnered attention, the company's delay in filing its 10-Q and the resignation of key executives have led investors to adopt a cautious stance regarding its future sales cycles and market performance, potentially impacting further stock price volatility.
See More
Fennec Pharmaceuticals Initiates PEDMARK® Clinical Study
- Clinical Study Launch: Fennec Pharmaceuticals announced that the Tampa General Hospital Cancer Institute is initiating a clinical study to evaluate the clinical utility of PEDMARK® in reducing ototoxicity in adolescent and adult cancer patients receiving cisplatin, which is expected to provide crucial data for future clinical research.
- Ototoxicity Risk Assessment: The study will analyze real-world clinical data and audiology monitoring to improve strategies for managing ototoxicity, which is anticipated to enhance patients' quality of life and reduce long-term hearing loss due to ototoxicity.
- FDA Approval Context: PEDMARK® is the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment, indicated for pediatric patients aged one month and older, representing significant market potential, especially among the approximately 500,000 cancer patients diagnosed annually.
- Collaborative Research Significance: The collaboration between Tampa General Hospital and the USF Health Morsani College of Medicine underscores the commitment to otoprotective strategies, which is expected to drive broader recognition of PEDMARK® in clinical applications, further solidifying Fennec Pharmaceuticals' leadership in the field of ototoxicity prevention.
See More
PEDMARK® Shows Promise for Hearing Preservation in Head and Neck Cancer Patients
- Safety and Integration: The study indicates that PEDMARK® can be safely administered ≥ six hours after cisplatin treatment in head and neck cancer patients, integrating easily into real-world care plans, thereby ensuring that cisplatin's antitumor activity remains unaffected and enhancing clinical feasibility.
- Hearing Preservation Potential: Most high-risk patients receiving PEDMARK® demonstrated no measurable hearing loss during or after treatment, despite pre-existing hearing impairment, highlighting the drug's potential to address cisplatin-induced hearing loss and potentially improve patients' quality of survivorship.
- Clinical Application Expansion: The findings support further exploration of PEDMARK® in additional patient populations and tumor types, particularly among high-risk patients, which may drive broader clinical adoption to meet unmet medical needs.
- Long-term Value and Market Outlook: Fennec Pharmaceuticals' Chief Medical Officer noted that these new findings demonstrate the feasibility and long-term value of PEDMARK®, potentially facilitating its wider clinical adoption in high-risk patient populations, thereby presenting significant market opportunities for the company.
See More
B. Riley Begins Coverage of Fennec Pharmaceuticals Inc. with a Buy Rating and $16 Price Target
Company Overview: Fennec Pharmaceuticals has initiated coverage with a buy rating from B. Riley.
Target Price: The target price set for Fennec Pharmaceuticals is $16.
See More
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
- Share Disposition: On December 24, 2025, Southpoint Capital Advisors disposed of 1 million common shares of Fennec Pharmaceuticals at $7.50 per share, reducing its ownership stake to approximately 8% of the outstanding shares.
- Market Strategy: This sale indicates a strategic adjustment in Southpoint's investment portfolio, as it still controls 2.7 million shares, but the reduced stake may reflect a cautious outlook on market conditions.
- Compliance Disclosure: The press release serves to comply with securities regulations, ensuring transparency and maintaining market trust, highlighting Southpoint's commitment to regulatory adherence.
- Future Outlook: Depending on market and other conditions, Southpoint may further adjust its ownership of Fennec through market transactions or other means, indicating flexibility in its investment strategy.
See More
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
- Share Disposition: On December 24, 2025, Southpoint Capital Advisors disposed of 1 million common shares of Fennec Pharmaceuticals at $7.50 per share, reducing its ownership stake to approximately 8% of the total outstanding shares.
- Market Strategy: The shares sold represent about 2.93% of Fennec's total outstanding shares, indicating Southpoint's flexible investment strategy in response to changing market conditions, which could impact Fennec's stock performance.
- Ownership Adjustment: Following this transaction, Southpoint retains control over 2.7 million shares of Fennec, reflecting ongoing interest in the company, although the reduction may suggest a response to short-term market volatility.
- Future Outlook: Southpoint indicated that it may further adjust its ownership of Fennec based on market and other conditions, demonstrating its proactive and flexible approach to investment management.
See More
Solas Capital Initiates New Position in Kyndryl
- New Position Disclosure: On February 17, 2026, Solas Capital Management disclosed a new position in Kyndryl by acquiring 407,634 shares valued at $10.83 million, reflecting both confidence in the company and concerns over market volatility.
- Asset Allocation Change: This acquisition represents 6.14% of Solas Capital's reportable assets under management, indicating Kyndryl's significance in the investment portfolio, despite its stock price plummeting by 67.5% over the past year.
- Financial Performance Overview: Kyndryl's latest financial metrics reveal a trailing twelve-month revenue of $15.12 billion and a net income of $249 million, with a market capitalization of $3.06 billion, highlighting ongoing challenges in the IT infrastructure services sector, particularly in its partnership with IBM.
- Uncertain Market Outlook: While Solas Capital's investment in Kyndryl has garnered attention, the company's delay in filing its 10-Q and the resignation of key executives have led investors to adopt a cautious stance regarding its future sales cycles and market performance, potentially impacting further stock price volatility.
See More
Fennec Pharmaceuticals Initiates PEDMARK® Clinical Study
- Clinical Study Launch: Fennec Pharmaceuticals announced that the Tampa General Hospital Cancer Institute is initiating a clinical study to evaluate the clinical utility of PEDMARK® in reducing ototoxicity in adolescent and adult cancer patients receiving cisplatin, which is expected to provide crucial data for future clinical research.
- Ototoxicity Risk Assessment: The study will analyze real-world clinical data and audiology monitoring to improve strategies for managing ototoxicity, which is anticipated to enhance patients' quality of life and reduce long-term hearing loss due to ototoxicity.
- FDA Approval Context: PEDMARK® is the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment, indicated for pediatric patients aged one month and older, representing significant market potential, especially among the approximately 500,000 cancer patients diagnosed annually.
- Collaborative Research Significance: The collaboration between Tampa General Hospital and the USF Health Morsani College of Medicine underscores the commitment to otoprotective strategies, which is expected to drive broader recognition of PEDMARK® in clinical applications, further solidifying Fennec Pharmaceuticals' leadership in the field of ototoxicity prevention.
See More
PEDMARK® Shows Promise for Hearing Preservation in Head and Neck Cancer Patients
- Safety and Integration: The study indicates that PEDMARK® can be safely administered ≥ six hours after cisplatin treatment in head and neck cancer patients, integrating easily into real-world care plans, thereby ensuring that cisplatin's antitumor activity remains unaffected and enhancing clinical feasibility.
- Hearing Preservation Potential: Most high-risk patients receiving PEDMARK® demonstrated no measurable hearing loss during or after treatment, despite pre-existing hearing impairment, highlighting the drug's potential to address cisplatin-induced hearing loss and potentially improve patients' quality of survivorship.
- Clinical Application Expansion: The findings support further exploration of PEDMARK® in additional patient populations and tumor types, particularly among high-risk patients, which may drive broader clinical adoption to meet unmet medical needs.
- Long-term Value and Market Outlook: Fennec Pharmaceuticals' Chief Medical Officer noted that these new findings demonstrate the feasibility and long-term value of PEDMARK®, potentially facilitating its wider clinical adoption in high-risk patient populations, thereby presenting significant market opportunities for the company.
See More
B. Riley Begins Coverage of Fennec Pharmaceuticals Inc. with a Buy Rating and $16 Price Target
Company Overview: Fennec Pharmaceuticals has initiated coverage with a buy rating from B. Riley.
Target Price: The target price set for Fennec Pharmaceuticals is $16.
See More
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
- Share Disposition: On December 24, 2025, Southpoint Capital Advisors disposed of 1 million common shares of Fennec Pharmaceuticals at $7.50 per share, reducing its ownership stake to approximately 8% of the outstanding shares.
- Market Strategy: This sale indicates a strategic adjustment in Southpoint's investment portfolio, as it still controls 2.7 million shares, but the reduced stake may reflect a cautious outlook on market conditions.
- Compliance Disclosure: The press release serves to comply with securities regulations, ensuring transparency and maintaining market trust, highlighting Southpoint's commitment to regulatory adherence.
- Future Outlook: Depending on market and other conditions, Southpoint may further adjust its ownership of Fennec through market transactions or other means, indicating flexibility in its investment strategy.
See More
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
- Share Disposition: On December 24, 2025, Southpoint Capital Advisors disposed of 1 million common shares of Fennec Pharmaceuticals at $7.50 per share, reducing its ownership stake to approximately 8% of the total outstanding shares.
- Market Strategy: The shares sold represent about 2.93% of Fennec's total outstanding shares, indicating Southpoint's flexible investment strategy in response to changing market conditions, which could impact Fennec's stock performance.
- Ownership Adjustment: Following this transaction, Southpoint retains control over 2.7 million shares of Fennec, reflecting ongoing interest in the company, although the reduction may suggest a response to short-term market volatility.
- Future Outlook: Southpoint indicated that it may further adjust its ownership of Fennec based on market and other conditions, demonstrating its proactive and flexible approach to investment management.
See More
